The consensus among analysts is that Editas Medicine, Inc. (EDIT) is an Overweight stock at the moment, with a recommendation rating of 2.3. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 5 out of 11 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.81.

Editas Medicine, Inc. (NASDAQ:EDIT) trade information

Sporting 1.45% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the EDIT stock price touched $36.78- or saw a rise of 20.23%. Year-to-date, Editas Medicine, Inc. shares have moved -0.91%, while the 5-day performance has seen it change -11.6%. Over the past 30 days, the shares of Editas Medicine, Inc. (NASDAQ:EDIT) have changed 8.39%. Short interest in the company has seen 9.08 Million shares shorted with days to cover at 8.82.

Editas Medicine, Inc. (EDIT) estimates and forecasts

Figures show that Editas Medicine, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -3.68% over the past 6 months, with this year growth rate of 12.69%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 1.2% and -153.1% for the next quarter. Revenue growth from the last financial year stood is estimated to be +17%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.8% over the past 5 years. Earnings growth for 2020 is a modest -14.6% while over the next 5 years, the company’s earnings are expected to increase by 0%.

Editas Medicine, Inc. (NASDAQ:EDIT)’s Major holders

Insiders own 2.41% of the company shares, while shares held by institutions stand at 75.78% with a share float percentage of 77.65%. Investors are also buoyed by the number of investors in a company, with Editas Medicine, Inc. having a total of 291 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 5.34 Million shares worth more than $105.81 Million. As of March 30, 2020, ARK Investment Management, LLC held 9.7% of shares outstanding.

The other major institutional holder is Nikko Asset Management Americas, Inc., with the holding of over 5.11 Million shares as of March 30, 2020. The firm’s total holdings are worth over $101.29 Million and represent 9.29% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and Smallcap World Fund. As of January 30, 2020, the former fund manager holds about 4.5% shares in the company for having 2473842 shares of worth $65.38 Million while later fund manager owns 1.76 Million shares of worth $52.11 Million as of December 30, 2019, which makes it owner of about 3.2% of company’s outstanding stock.